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Comprehensive prenatal care has be
come the hallmark of modern obstetrical prac
tice. Awareness by both physicians and pa
tients that such care is necessary for
satisfactory perinatal outcome has led to the es
tablishment of an obstetrical subspecialty, Ma
ternal Fetal Medicine, to provide a higher level
of prenatal care and to increase our knowledge
of perinatal events. Many of the management
techniques currently being used for high-risk
pregnancies can be readily applied to the rou
tine obstetrical population. The additional physi
cian time and laboratory tests required are mini
mal, and the early identification and prevention
of perinatal complications will eliminate the
need for "crisis" medicine.
Identification of the High-Risk Patient
The first step toward initiating a manage
ment plan for a high-risk pregnancy is recogni
tion that a poor perinatal outcome is possible.
Early identification of the "at-risk" fetus begins
with the first antenatal screening visit. Although
most conditions associated with an adverse ma
ternal or fetal outcome have long been recog
nized, I have found it helpful to use a risk-scor
ing approach that provides a semiquantitative
risk estimate. 1· This method takes into consid
eration various historical, physical, and labora
tory data to generate a numerical risk score; in
general, as the risk score increases, the likeli
hood of an unfavorable perinatal outcome also
increases. Depending on the clinical setting,
one quarter to one third of all pregnancies will
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be identified prospectively as high risk and can
be expected to experience the majority of peri
natal mortality and morbidity. It is in this group
of high-risk patients that recently developed
methods of fetal surveillance are likely to find
their greatest value. While details of this risk
scoring system are beyond the scope of this
discussion, it should be mentioned that the Vir
ginia State Department of Health currently has
plans to implement a risk-scoring system into
the state health care system.
Dr. Robert Petr es has previously ad
dressed the problem of identification of the
high-risk gravida. Although his classification of
pregnancies into various risk categories based
on the worst single antepartum complication is
a different approach from the numerical risk
scoring system, he accomplishes much the
same result-prospective identification of the
patient at risk for an adverse perinatal outcome.
Management
Ideally, every woman should be seen by
an obstetrician prior to conception. At this time
the physician may identify medical problems
that should receive attention. The patient should
be made aware of the importance of early pre
natal care and be encouraged to seek an early
diagnosis of pregnancy. The patient-physician
relationship established at the preconception
visit will encourage this.
Office management of the high-risk grav
ida begins with the initial visit. Postconception,
patients should be seen as soon as possible in
the office. It is difficult to convince patients of the
importance of prenatal care if they must wait 3
to 4 weeks for their first postconception visit. If
the physician is not readily available, the initial
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office screening should be performed by a
nurse. The patient's blood pressure and urine
should be checked, a pregnancy test performed
to confirm pregnancy, and a check list history
taken to identify any significant problems that
may require immediate attention by the physi
cian. If the patient is entirely normal with a neg
ative history, she may be scheduled to see the
physician at a later date; however, if a problem
is identified on the screening visit, it should be
dealt with as soon as possible.
Initial Visit
The objectives of the initial visit are to de
termine the health of the mother and fetus, to
determine the gestational age of the fetus, and
to initiate a plan for continuing obstetrical care.
A thorough physical should be performed and a
complete history taken. Special attention should
be given to a chronological listing of all previous
pregnancies and include length of gestation,
fetal weight, route of delivery, and any maternal
or fetal complications Past obstetrical perform
ance is the single most important historical fact
that may predict potential problems during the
current pregnancy The date and character of
the last two menstrual periods should be in
cluded at this time. Particular attention should
be given to the funduscopic exam, thyroid,
heart, lungs, breasts, fundal height, and to the
presence or absence of fetal heart tones.
Routine laboratory work which should be
performed on all pregnant patients is listed be
low:
1 CBC
2. Urine culture
3. Urinalysis
4 VDRL
5. Blood type and Rh titers
6. Atypical blood group antibodies
7. Pap smear
8. Gonococcal culture
9. Rubella titers
10. Two-hour postprandial blood sugar
Additional laboratory work may be needed in
selected cases depending on the patient's his
tory and physical findings. The more common
additional studies to evaluate patients with hy
pertension or chronic renal disease include a
SMA 12, SMA 6, and a 24-hour urine collection
for protein and creatinine clearance. Diabetic
patients will need blood sugar determinations
and an ophthalmology consultation in addition
10 /

JARRELL: HIGH-RISK GRAVIDA

to the tests for renal evaluation. Supplemental
tests such as thyroid function tests, parathyroi<;l
function tests, and liver function tests should be
obtained on those patients where historical @r
physical data suggest possible problems. The
CBC, urine culture, and the two-hour posh
prandial blood sugar should be repeated at 32
weeks gestation because of the complications
associated with undiagnosed anemia, pyelone
phritis, and diabetes in the third trimester. In
routine uncomplicated pregnancies no addi-·
tional laboratory tests need be repeated. Atypi
cal antibodies may develop in patients who be
come sensitized to various blood group
antigens and many of these atypical antibodies;
can cause erythroblastosis and intrauterine fetal:
death. These patients need to be treated in a;
fashion similar to an Rh negative sensitized pa
tient. The blood bank should provide informa
tion concerning which of the atypical antibodies
are possible causes of erythroblastosis. Rubella
titers should be included in all pregnant women;
patients with positive rubella titers can be reas
sured that rubella will not be a problem during
the course of pregnancy Patients with negative
rubella titers may be vaccinated in the post
partum period If the two-hour postprandial
blood sugar is greater than 120 mg/%, a glu
cose tolerance test (GTT) should be performed
to rule out gestational diabetes. Since the de
mand for insulin increases with gestation a sec
ond two-hour postprandial blood sugar or GTT
should be performed at 32 weeks.
The frequency of subsequent office visits
must be determined according to the needs of
the patient as should the need for additional lab
oratory work and possible antenatal hospital
ization.
Regardless of the patient's high risk
classification the objectives of prenatal manage
ment remain the same and include evaluation of
the maternal condition, fetal condition, and ges
tational age These must be considered on
each prenatal visit. Although the number of ad
ditional visits, consultations and laboratory work
necessary for proper evaluation should be indi
vidualized there are certain management tech
niques that apply to all patients in the first, sec
ond and third trimesters of pregnancy
First Trimester
Maternal condition should be evaluated
with a history and physical examination, routine

laboratory work, and selected laboratory work
and procedures. when indicated, to establish a
baseline medical status during the first trimes
ter.
Fetal condition is difficult to assess in the
first trimester and very little can be done to alter
the course of pregnancy at this stage of gesta
tion. Progressive fundal growth should be rou
tinely documented as a means of assessing
fetal condition. If uterine growth is abnormal or
vaginal bleeding should ensue, ultrasonic evi
dence of a normal or abnormal gestation sac or
fetus will provide prognostic data; this may lead
to earlier intervention in cases of obvious preg
nancy loss.
Gestational age must be accurately as
sessed during the first and second trimesters of
pregnancy. The difficulty in accurately assess
ing gestational age in the third trimester is well
known. The date, duration and character of the
last menstrual period (LMP) should be clearly re
corded in the chart. Additional information re
garding the regularity of the patient's menstrual
cycle and her most recent means of birth con
trol should be documented. Uterine size during
the first trimester of pregnancy is also useful in
determining gestational age.
Second Trimester

Maternal condition should be evaluated
routinely with blood pressure determination,
maternal weight gain, and urinalysis for protein,
glucose and acetone. The frequency of visits
and the need for additional lab work and pos
sible hospitalization must be determined at this
time. The minimum interval between office visits
for patients with otherwise uncomplicated preg
nancies should be every four weeks.
Although very little can be done to alter
the course of pregnancy at this stage in gesta
tion, fetal condition can still be evaluated by
monitoring progressive fundal growth and the
development of fetal movement. Should prob
lems arise, many of the more serious fetal con
ditions can be evaluated with a careful ul
trasound examination.
The second trimester of pregnancy con
tains many gestational landmarks that are im
portant in determining gestational age for future
management. The appearance of the first fetal
heart tones heard with an unamplified fetoscope
is a reliable means of determining gestational
age; these should be heard at 20 weeks, plus

or minus 1 week, in the majority of pregnancies.
From 1 7 weeks on patients should be seen
weekly until fetal heart tones have been heard
with the unamplified fetoscope In addition, a
patient should also be asked to mark the date
when she first feels fetal movement. If towards
the end of pregnancy fetal movement has been
present for more than 22 weeks and fetal heart
tones have been present for 20 weeks, the pa
tient has a 95% chance of being at least 39 to
40 weeks pregnant. Fundal height should be re
corded as accurately as possible in the second
trimester of pregnancy because of the narrow
range of standard deviation in uterine size that
occurs at this time. The large difference in uter
ine sizes that occurs with infants who are small,
average or large for their gestational age does
not usually occur until the third trimester of
pregnancy. If fetal gestational age can not be
reliably determined, an ultrasound study for
.biparietal diameter should be obtained.
Third Trimester

The mother and fetus both require in
creased surveillance during this period of gesta
tion as numerous complications may arise in
previously normal pregnancies Early recogni
tion and proper intervention will decrease the
perinatal morbidity and mortality associated
with many of these developing problems
Maternal condition should be evaluated
every two weeks during the third trimester and
every week during the last month. Closer obser
vation may be required in selected patients.
Maternal condition should be evaluated with
routine blood pressure, urinalysis, and weight
gain observation. Routine laboratory work
which should be repeated early in the third tri
mester of pregnancy includes a CBC, a two
hour postprandial blood sugar, and a urine cul
ture. More frequent evaluation of renal function
tests, blood sugars and additional laboratory
work will be necessary in selected patients.
Evaluation of fetal condition during the
third trimester of pregnancy has become a ma
jor part of antepartum fetal management. Both
biophysical and biochemical means of fetal
monitoring are available. At the present time,
the only useful biochemical test for evaluating
fetal well-being is urinary or serum estriols.
However, if estriols are to be used to predict
fetal compromise, specimens must be collected
daily and the results must be available to the
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physician within 12 hours. An isolated or weekly
estriol value should not be used to monitor fetal
well-being in complicated pregnancies.
The biophysical tests of fetal well-being in
clude nonstressed fetal heart rate monitoring
(NST) and an oxytocin challenge test (OCT). 3
The decision as to when to start antenatal fetal
heart rate monitoring should be based on the in
dividual patient and the clinical situation. Mon
itoring may be indicated as early as 26 to 28
weeks of gestation in patients with advanced
hypertension or diabetes, or delayed until 42
weeks in a previously uncomplicated post-term
pregnancy. In general, antepartum fetal heart
rate monitoring should not be performed prior to
the time in gestation when the physician would
consider terminating a pregnancy because of
fetal indications. There are limited data avail
able on the use of antepartum monitoring prior
to 30 weeks of gestation.
Indications for antepartum fetal heart rate
monitoring are any pregnancy at risk for uter
oplacental insufficiency. There are no con
traindications to the NST. The oxytocin chal
lenge test is associated with the following
contraindications: ruptured membranes, sus
pected abruptio placenta, undiagnosed uterine
bleeding, placenta previa, previous cesarean
section, incompetent cervix, previous pre
mature labor and polyhydramnios. In addition,
the OCT has not been shown to be of value in
the management of erythroblastosis fetalis. In
general, negative OCT or reactive NST allows
the clinician to avoid unnecessary premature in
tervention and has a false-positive rate (fetal
death in 1 week of monitoring) of 2 to 5 per
1 000 A nonreactive NST or a positive OCT
alerts the physician to possible fetal com
promise and may be an indication for inter
vention before fetal death or irreversible dam
age occurs.
The NST has been shown to be as reliable
as the OCT. Because of the reliability and sim
plicity of the NST, this monitoring technique has
become the primary means of antenatal fetal
monitoring here at the Medical College of Vir
ginia. An outline of procedure for patient care is
listed below.
1. The "at-risk" patient is identified us
ing clinical risk assessment and scor
ing techniques at the first antenatal
visit and as problems develop during
gestation.
I 2
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Based on the clinical situation the
NST may be started as early as 28
weeks.
3 The patient is followed with weekly
NSTs, as long as she remains reac
tive.
4. Any inadequate NST is repeated
within 24 hours. Any nonreactive
NST is evaluated the same day with
an oxytocin challenge test.
o If the OCT is negative, the patient is
scheduled to have a NST the next
week.
6. A suspicious, hyperstimulation, or
unsatisfactory OCT is repeated
within 24 hours.
7. Urinary or serum estriols may be ob
tained for additional information, de
pending on the clinical situation, and
must be collected daily to be useful.
8. If a nonreactive NST is followed by a
positive OCT, serious consideration
must be given to delivering the fetus.
At this time, amniocentesis may be
performed and if the amniotic fluid
indicates fetal maturity, or meco
nium-stained fluid is found, the fetus
should be delivered.
9. If the amniotic fluid is clear and there
is evidence of fetal pulmonary im
maturity, a decision is made based
on which risk is greater, prematurity
or the in utero environment.
1 0 In the face of low or falling estriols,
with a nonreactive NST and/or a
positive OCT, we at MCV recom
mend delivering the fetus if it is vi
able.
11. If the estriols are stable and in the
normal range, with a nonreactive
NST or a positive OCT. the situation
is ambiguous. A decision to await
further maturation or to deliver the
patient may be appropriate. Clinical
judgment based on the overall as
sessment of the maternal status,
pregnancy duration. and the condi
tion of the fetus is required.
Determination of gestational age in the
third trimester of pregnancy is indeed difficult.
Ultrasound provides information about fetal size
but does not differentiate between the small
premature infant and the standard gestational

age term infant. To predict gestational age re
liably, information from the first and second tri
mesters must be available. During the third
trimester of pregnancy the emphasis shifts from
gestational age to determination of fetal matu
rity Without adequate clinical data concerning
gestational age or when premature interruption
of pregnancy is being considered prior to 39
weeks, I advocate amniocentesis for a lecithin
sphingomyelin (L/S) ratio.

Summary

Recognition of those patients at risk for a
poor perinatal outcome is the most important
step in reducing perinatal morbidity and mortal
ity. Once at-risk patients are recognized, in
tensive observation with frequent assessments
of maternal condition, fetal condition, and ges
tational age can be accomplished with minimal
additional physician time and laboratory tests.
The decision of when or when not to intervene
in a pregnancy is not an easy one and should
be based on all available data, an important
part of which is information collected during the
first and second trimester of pregnancy Re
gional perinatal consultation services should be

used more frequently for patients with manage
ment problems. Developing problems should be
treated aggressively with antepartum hospital
ization, intensive observation and evaluation,
and consultation. Proper assessment of mater
nal condition, fetal condition, and gestational
age will prevent many of the more serious com
plications and may allow the patient to remain in
her own community under the direct care of her
local physician. If, however, the patient requires
a level of care that cannot be provided in her
own community, she should be transferred to a
regional perinatal center without hesitation.
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